ReviewHematology. American Society of Hematology. Education Program2020
Optimizing the management of chronic pain in sickle cell disease.
Review in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07530965 (A Single Arm/ Open Label Feasibility Trial of Omega-3- Fatty Acids in Children With Sickle Cell Disease), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Arm/ Open Label Feasibility Trial of Omega-3- Fatty Acids in Children With Sickle Cell Disease
Who cites it
38 citing papers in PubMed, 50 citations in OpenAlex.
- Trial
- Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease.European journal of haematology · 2025Trial
- Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease.JAMA network open · 2026Article
- A Qualitative Phenomenological Study of Treatment Options for Patients with SCD and Chronic Pain: Buprenorphine-Naloxone or Full-Agonist Therapy.International journal of environmental research and public health · 2026Article
- Preliminary Benefits of In-Home Virtual Reality for Chronic Pain in Sickle Cell Disease: Pilot Randomized Trial.Biomedicines · 2026Article
- Sickle cell vaso-occlusive episodes correlate with the magnetic heterogeneity of red blood cells.Blood advances · 2026Article
- Buprenorphine for Children and Adolescents with Sickle Cell Disease: A Scoping Review.Children (Basel, Switzerland) · 2026Review
- Gene expression profiling identifies potential biomarkers for vaso-occlusive episodes in sickle cell disease.JCI insight · 2026Article
- Low bone mineral density and pain impact in adults with sickle cell disease.Blood advances · 2026Article
- Chronic pain in the aging adult with sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Acupressure alleviates pain and clinical symptoms in patients with sickle cell disease.Blood advances · 2025Article
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
- Patient Perspectives on Enhancing Clinician Communication About Pain in Sickle Cell Disease.Research square · 2025Article
- Innovative approaches to managing chronic multimorbidity: A multidisciplinary perspective.World journal of clinical cases · 2025Article
- Hospital Readmissions Among People With Sickle Cell Disease.JAMA network open · 2025Article
- Article
- Clinician attitudes toward palliative care to enhance the quality of life for patients with sickle cell disease.Journal of sickle cell disease · 2025Article
- Altered cerebral blood flow and functional connectivity in sickle cell disease.Journal of sickle cell disease · 2025Article
- Behavioral and transcriptional effects of age in HbSS-BERK humanized SCD mice.Journal of sickle cell disease · 2025Article
- End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care.Hematology. American Society of Hematology. Education Program · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain in sickle cell disease (SCD) refers to pain present on most days lasting over six months. It can start during childhood and the prevalence increases with age. By adulthood, over 55% of patients experience pain on over 50% of days; 29% reporting pain on 95% of days. The true prevalence of chronic pain in SCD is likely underappreciated as it is mostly managed at home. Patients with chronic pain and SCD frequently seek acute care for exacerbation of underlying chronic pain difficult to distinguish from their usual acute vaso-occlusive crises. When treating chronic pain in SCD, the challenge is distinguishing between non-SCD related etiologies versus chronic pain resulting from SCD pathophysiological processes. This distinction is important to delineate as it will drive appropriate management strategies. Chronic pain in SCD has profound consequences for the patient; is often associated with comorbid psychiatric illnesses (depression and anxiety), not dissimilar from other chronic pain syndromes. They may also experience challenges with sleep hygiene, various somatic symptoms, and chronic fatigue that impair quality of life. How best to treat chronic pain in SCD is not definitively established. Both acute and chronic pain in SCD is typically treated with opioids. Emerging data suggests that chronic opioid therapy (COT) is a suboptimal treatment strategy for chronic pain. This review will discuss the complexity of managing chronic pain in SCD; pain that may be dependent or independent of the underlying SCD diagnosis. We will also describe alternative treatment approaches to high-dose COT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.